2021罗氟司特治疗支气管哮喘的最新研究进展

Roflumilast can be used to treat certain types of asthma. For example, it can be used for neutrophilic asthma because of its significant inhibitory effect on neutrophil inflammation. It can also reduce early-onset asthma reactions and delayed-onset asthma reactions caused by exogenous substances through its anti-inflammatory mechanism, so it can also be used for the treatment of allergic asthma. Because of its enhancing effect on ICS and montelukast, it is mainly used as an auxiliary drug for conventional treatment, and the recommended dosage is 500 ug/d.

How about 2021?

To study the effect of roflumilast in the treatment of acute exacerbation of bronchial asthma (BA) and its effects on lung function and serological indicators. 128 patients with acute exacerbation of BA were selected and divided into a roflumilast group and a control group with 64 cases each according to the random number table method. The control group was given conventional treatment + budesonide suspension, and the roflumilast group was given conventional treatment + budesonide suspension + roflumilast. After 7 days of continuous treatment, the two groups were observed before and after treatment such as forced vital capacity (FVC), peak expiratory flow rate (PEF), forced expiratory volume in first second (FEV1) and other lung function indicators, the ratio of airway wall area to total airway cross-sectional area (WA%), bronchial wall thickness and bronchial outer diameter ratio (T /D) and other airway remodeling indicators, serum levels of inflammatory factors such as interferon gamma (INF-γ), tumor necrosis factor-α (TNF-α), and interleukin-17 (IL-17), serum levels of T cells such as CD4+, CD8+, CD4+/CD8+, and adverse reactions.

Results After treatment, the FVC, PEF, FEV1 and serum INF-γ, CD4+, CD4+/CD8+ levels in the roflumilast group were higher than those in the control group (P<0.05), while the WA%, T/D and serum TNF-α, IL-17 and CD8+ levels were lower than those in the control group (P<0.05). The total effective rate of the roflumilast group was better than that of the control group (P<0.05). There were no serious adverse reactions in both groups. Conclusion: Roflumilast in the treatment of acute exacerbation of BA can correct the body's inflammatory immune imbalance, inhibit airway remodeling, improve lung function and serological indicators, improve efficacy, and is safe and reliable.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.